Home

RegeneRx Pipeline

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.

RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications.

Learn More

Letter to Stockholders 2020 Letter to Stockholders 2020

March 18, 2020 Advisory: Update on Phase 3 Dry Eye Trial Amid COVID-19 Virus


Latest News
Mar 18, 2020

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on...

Feb 13, 2020

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...

More >

Subscribe
Sign up below to receive investor news updates from RegeneRx
* Required Fields